Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-0174 in Advanced Solid Tumors
NCT07885267Phase 1Completed
- Sponsor
- Antido Therapeutics
- Start
- Nov 2023
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AT-0174 in solid tumor, sponsored by Antido Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 28 days, Treatment-Emergent Adverse Events and 1 more. Started Nov 2023; status: completed.
02
Drugs
AT-0174
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07885267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07885267.